There are currently 363 clinical trials in Stanford, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Stanford University, Stanford University School of Medicine, Stanford University Medical Center and Stanford Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NCT04989803
Recruiting
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Relapsed and/or Refractory B-cell Lymphoma
Register for Updates
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
NCT04392622
Recruiting
This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Stanford University, Stanford, California
Conditions: Xerostomia
Register for Updates
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428
Recruiting
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Stanford Cancer Institute, Stanford, California
Conditions: Carcinoma, Non-small-Cell Lung
Register for Updates
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Stanford University Medical Center, Stanford, California
Conditions: Multiple Myeloma
Register for Updates
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037
Recruiting
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Stanford Hospital- Site Number : 8400008, Stanford, California
Conditions: Lung Transplant Rejection
Register for Updates
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
NCT05101551
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/22/2025
Locations: Stanford University, Stanford, California
Conditions: Acute Myeloid Leukemia
Register for Updates
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686
Recruiting
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: Stanford University Medical Center, Stanford, California +1 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the th... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
05/21/2025
Locations: Stanford University, Stanford, California
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Global Study of Del-desiran for the Treatment of DM1
NCT06411288
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
05/21/2025
Locations: Stanford University, Stanford, California
Conditions: DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
Register for Updates
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Stanford Cancer Center, Stanford, California
Conditions: Glioblastoma
Register for Updates
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022
Recruiting
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Site US10028, Stanford, California
Conditions: Prostate Cancer
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Stanford Hospital and Clinics, Stanford, California
Conditions: Mitral Valve Regurgitation
Register for Updates